Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Apr 4;344(6179):49-51.
doi: 10.1126/science.1250672.

Immunology. Immune activation with HIV vaccines

Anthony S Fauci  1 , Mary A Marovich, Carl W Dieffenbach, Eric Hunter, Susan P Buchbinder
Affiliations
Comment

Immunology. Immune activation with HIV vaccines

Anthony S Fauci et al. Science. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. HIV-Vaccine Induced Immune Response Interactions
Immune activation associated with HIV vaccination theoretically can lead to increased infection due to the activation of CD4+ T cells during the immune response. The level of protection seen with a vaccine can be viewed as the balance between the responses to the vaccine that lead to susceptibility to infection counterbalanced by the responses that favor protection.
See this image and copyright information in PMC

Comment on

References

    1. Rerks-Ngarm S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209–2220. - PubMed
    1. Robb ML, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis. 2012;12(7):531–7. - PMC - PubMed
    1. Buchbinder S, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881. - PMC - PubMed
    1. McElrath J, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008;372:1894. - PMC - PubMed
    1. Gray GE, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011;11(7):507–15. - PMC - PubMed